Ingenia Therapeutics expects USD 5 million MK-8748 milestone payment from Merck unit Eyebiotech

• Ingenia Therapeutics expects to receive a milestone payment tied to MK-8748, licensed to Merck unit Eyebiotech in 2022.
• Payment amount set at USD 5 million, triggered by the start of a global Phase 3 trial in diabetic macular edema.
• Invoice issued on Sept. 25, 2026, marking the milestone confirmation date under the license agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ingenia Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260928900639), on September 28, 2026, and is solely responsible for the information contained therein.